Bruker (NASDAQ:BRKR) Sets New 52-Week High - Should You Buy?

Key Points

• Bruker shares reached a new 52-week high of $65.48 and were recently trading around $65.25, up 3.2%. The stock’s analyst consensus is “Moderate Buy,” with a $57.71 average price target, though targets range from $50 to $80.
• The company beat quarterly earnings expectations, reporting $0.49 EPS versus the $0.38 consensus, while revenue rose 5.2% year over year to $838.5 million but fell short of estimates.
• Bruker declared a quarterly dividend of $0.05 per share, equal to a 0.3% annualized yield. Institutional investors own 79.52% of the stock, while insiders own 27.20%; one vice president recently sold 2,000 shares.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $65.48 and last traded at $65.25, with a volume of 222753 shares trading hands. The stock had previously closed at $64.51.

Analyst Ratings Changes

Several research firms have weighed in on BRKR. UBS Group assumed coverage on Bruker in a report on Wednesday, September 9th. They set a "neutral" rating and a $65.00 price target for the company. Leerink Partners increased their price objective on shares of Bruker from $60.00 to $80.00 and gave the stock an "outperform" rating in a research report on Tuesday. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research note on Wednesday, August 5th. Weiss Ratings restated a "sell (d+)" rating on shares of Bruker in a report on Monday, August 31st. Finally, Citigroup reduced their price target on shares of Bruker from $60.00 to $53.00 and set a "hold" rating for the company in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $57.71.

Bruker Trading Up 3.2%

The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The stock has a market capitalization of $10.14 billion, a PE ratio of -95.06, a P/E/G ratio of 1.94 and a beta of 1.26. The company has a 50 day moving average of $58.71 and a two-hundred day moving average of $51.20.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. Bruker's revenue was up 5.2% on a year-over-year basis. During the same period last year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker's dividend payout ratio (DPR) is currently -28.57%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president directly owned 134,806 shares of the company's stock, valued at $7,127,193.22. This represents a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 27.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently added to or reduced their stakes in the business. Hsbc Holdings PLC acquired a new position in Bruker in the second quarter valued at approximately $5,252,000. Wellington Management Group LLP acquired a new stake in shares of Bruker during the 2nd quarter worth approximately $1,365,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Bruker during the 2nd quarter worth approximately $4,536,000. Deutsche Bank AG purchased a new position in shares of Bruker during the 2nd quarter valued at approximately $1,439,000. Finally, Edmond DE Rothschild Holding S.A. acquired a new position in shares of Bruker in the 2nd quarter valued at $169,899,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, chemicals, biological samples and industrial products. Its customers include academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, environmental laboratories and industrial manufacturers.

The company's portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray instruments, microscopy and surface-analysis platforms, molecular spectroscopy systems, and analytical tools for proteomics, spatial biology, metabolomics and materials research.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.